<unk> , sold under the brand name Aristada, is a long-acting injectable atypical antipsychotic that was developed by Alkermes. It is an N-acyloxymethyl prodrug of<unk>  that is administered via intramuscular injection once every four to eight weeks for the treatment of schizophrenia.<unk>  was approved by the U.S. Food and Drug Administration (FDA) on 5 October 2015.
Aripiprazole lauroxil
Electroconvulsive therapy
Brief psychotherapy
Desmethylclozapine
Serdexmethylphenidate/dexmethylphenidate
Clozapine
Lorpiprazole
Insight-oriented psychotherapy